Methods
our findings support the concept that adverse events lead to therapy discontinuation. 9 • Better-tolerated therapies that reduce healthcare system costs and improve patient experience are desirable.
• Limitations: A commercially insured population may not be representative of the entire US population nor of treatment patterns in other countries. Claims do not provide data on genotype, so patients treated beyond 24 weeks were presumed to have genotype 1, 4, or 6.
Miscoding or undercoding of claims may affect the accuracy of cost estimates.
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• Retrospective cohort analysis of healthcare claims from the i3 Ingenix LabRx database.
• Inclusion criteria: Treated with alfa/RBV during the identification period; AND ≥1 medical claim with an ICD-9 -CM code for CHC (070.41, 070.44, 070.51, 070.54, 070.7x) during the preindex period; AND initial prescription for both drugs filled within 14 days of one another.
• Exclusion criteria: <18 years of age; not continuously enrolled during the entire study period; not a new start or a therapy started at nonrecommended dose; diagnosis of other condition for which these drugs may have been used (e.g., hepatitis B, Hodgkin's lymphoma, multiple myeloma).
• Index date was the date of first fill for alfa/RBV within the identification period. Twelve months before was defined as the preindex period, and 12 months after was the postindex period.
• Treatment-emergent comorbid events were defined as a medical claim with a diagnosis for a condition in the postindex period that was not present in the preindex period.
• Net incremental cost was calculated as the difference between preindex and postindex costs for these comorbidities and their treatments, excluding cost of alfa/RBV.
• The mean incremental cost for treatment-emergent comorbid events in the postindex period was $6,377 (SD $22,326), $2,782 for medical and $3,595 for pharmacy claims.
• In the multivariate model, age ≥60 (P<0.01) and female gender (P<0.05) were significantly associated with higher charges . 
Background and Objectives

Proportion of Patients with a New Diagnosis of Treatment-Emergent
Comorbid Events in the Postindex Period
• Age, gender, region, and treatment duration were used in an exploratory multivariate model to identify factors that may be associated with these increased costs.
• Treatment duration was calculated as time to discontinuation of both alfa and RBV therapy for ≥60 Other specialty* 120 (9.5) Unknown 20 (1.6) * All individual specialties in "Other" are <2%
• Of 3,795 newly treated patients, 1,269 met the inclusion criteria.
• Most exclusions (2,274) were those who did not meet the continuous enrollment criteria.
• 14.2% discontinued treatment before week 12, 32.8% before week 24. Among patients who were treated for >24 weeks (e.g., patients with genotype 1, 4, or 6), 46.8% discontinued treatment by week 48. .
• Increase in non-drug-related charges were the highest ($6,015; SD 28,057) in patients who completed only 12 weeks of treatment and the lowest ($291; SD 17,308) in patients who completed the 48-week treatment. • For patients with CHC genotype 1, 48 weeks of pegylated interferon alfa (PEG-alfa) and ribavirin (RBV) is the standard treatment, whereas in patients with genotypes 2 and 3, 24 weeks is adequate.
Increase in charges from
• Patients who are able to maintain at least 80% adherence to their drug regimen have the highest likelihood of achieving sustained virologic response, but treatment-emergent comorbid events commonly limit adherence. [3] [4] [5] • 47.4% -77.5% of patients discontinue therapy prematurely in clinical care settings. [6] [7] [8] • Despite their frequency and affect on treatment, little is known about the cost associated with these adverse events. 9 The objective of this study was to estimate the incidence of treatment-emergent comorbid events and the incremental costs of treating these events in insured patients initiating PEG-alfa and RBV treatment for CHC.
Title: Incidence and Cost of Treatment-Emergent Comorbid Events in an Insured Population Receiving Treatment for Chronic Hepatitis C (CHC) Virus Infection
Authors: Sapra S 1 , Chang E 2 , Broder M 2 , L'Italien, G New treatment-emergent events were common, with 61.6% of patients having ≥ 1 event.
Anemia was identified in 29.2% of patients, fatigue in 16.4%, depression in 11.5%, and neutropenia in 10.9%. The mean incremental cost for the pre-defined treatment-emergent comorbid events in the post-index period was $6,377 (SD $22,326); $2,783 for medical and $3,595 for pharmacy claims. Age ≥ 60 and female gender were significantly associated with higher charges in the multivariate model.
CONCLUSIONS:
In an insured US cohort with CHC, treatment-emergent comorbidities with pegalfa/ RBV were common and increased cost by $6,000/treated patient. This excludes indirect costs and is therefore a conservative estimate. Costs might increase with the use of triple therapy with peg-alfa/RBV and a protease inhibitor, as additional treatment-emergent comorbid events may be expected. Better-tolerated therapies that reduce the financial burden on the healthcare system costs and improve patient experience are desirable.
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